These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28453946)

  • 41. Treatment of the genitourinary syndrome of menopause.
    Palacios S; Mejía A; Neyro JL
    Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
    Vicariotto F; Raichi M
    Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials.
    Pitsouni E; Grigoriadis T; Douskos A; Kyriakidou M; Falagas ME; Athanasiou S
    Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():45-56. PubMed ID: 30103082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.
    Cipriani S; Maseroli E; Ravelli SA; Vignozzi L
    Climacteric; 2023 Aug; 26(4):309-315. PubMed ID: 37288964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on management of genitourinary syndrome of menopause: A practical guide.
    Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
    Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements.
    Shim S; Park KM; Chung YJ; Kim MR
    J Menopausal Med; 2021 Apr; 27(1):1-7. PubMed ID: 33942583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genitourinary Syndrome of Menopause: A Narrative Review Focusing on Its Effects on the Sexual Health and Quality of Life of Women.
    Wasnik VB; Acharya N; Mohammad S
    Cureus; 2023 Nov; 15(11):e48143. PubMed ID: 38046779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genitourinary syndrome of menopause.
    Farrell Am E
    Aust Fam Physician; 2017; 46(7):481-484. PubMed ID: 28697291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.
    Pinkerton JV; Kaunitz AM; Manson JE
    Menopause; 2017 Dec; 24(12):1329-1332. PubMed ID: 29040220
    [No Abstract]   [Full Text] [Related]  

  • 50. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.
    Nappi RE; Martini E; Cucinella L; Martella S; Tiranini L; Inzoli A; Brambilla E; Bosoni D; Cassani C; Gardella B
    Front Endocrinol (Lausanne); 2019; 10():561. PubMed ID: 31496993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients.
    Li B; Duan H; Chang Y; Wang S
    Pharmacol Res; 2021 Feb; 164():105360. PubMed ID: 33307219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
    Jha S; Wyld L; Krishnaswamy PH
    Clin Breast Cancer; 2019 Aug; 19(4):e556-e562. PubMed ID: 31227415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What Is Genitourinary Syndrome of Menopause and Why Should We Care?
    Peters KJ
    Perm J; 2021 May; 25():. PubMed ID: 33970091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genitourinary syndrome of lactation: a new perspective on postpartum and lactation-related genitourinary symptoms.
    Perelmuter S; Burns R; Shearer K; Grant R; Soogoor A; Jun S; Meurer JA; Krapf J; Rubin R
    Sex Med Rev; 2024 Jun; 12(3):279-287. PubMed ID: 38757214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pelvic floor muscle rehabilitation for genitourinary syndrome of menopause: why, how and when?
    Mercier J; Dumoulin C; Carrier-Noreau G
    Climacteric; 2023 Aug; 26(4):302-308. PubMed ID: 37019140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study.
    Cuerva MJ; González SP; Lazaro-Carrasco De La Fuente J; Lopez FJ; Nieto C
    J Obstet Gynaecol; 2022 Oct; 42(7):3397-3399. PubMed ID: 35658728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An online survey on coping methods for genitourinary syndrome of menopause, including vulvovaginal atrophy, among Japanese women and their satisfaction levels.
    Ohta H; Hatta M; Ota K; Yoshikata R; Salvatore S
    BMC Womens Health; 2023 May; 23(1):282. PubMed ID: 37226145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.
    Crean-Tate KK; Faubion SS; Pederson HJ; Vencill JA; Batur P
    Am J Obstet Gynecol; 2020 Feb; 222(2):103-113. PubMed ID: 31473229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What should guide our patient management of vulvovaginal atrophy?
    Shapiro M
    Climacteric; 2019 Feb; 22(1):38-43. PubMed ID: 30452294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.